Psychiatry

Patients that had their medication selection guided by the GeneSight pharmacogenomic testing were 50% more likely to achieve remission and 30% more likely to achieve treatment response.

Patients with cannabis and cocaine use disorder have different impulsivity profiles, especially with relation to differences in attentional impulsiveness.

Results demonstrate potential to address a significant unmet for more than 30% of those suffering from treatment-resistant depression.

John Greden, MD, discussed the challenges physicians face in diagnosing, identifying, and treating depression, and the populations that are still severely underserved.

Darrell Kirch, MD, spoke at the APA’s annual meeting about the impact physician burnout has had and what can be done to address it and to improve clinician well-being.

Mayumi Okuda, MD, talked about what clinicians need to be doing and aware of in the identification of patients experiencing intimate partner violence.

Firearm use in the not guilty by reason of insanity population is more closely related to substance use and personality disorder than psychotic or mood disorders.

The associated PTSD comorbidities represent a significant public health problem that’s concomitant with increased disease burden and mortality.

The use of electroconvulsive therapy in patients with bipolar depression resulted in higher remission rates while showing similar response rates to unipolar major depression.

The algorithm is intended to help prevent mistakes caused by a slew of issues, from burnout at the end of a long day to overconfidence in decision-making.

This week on MDNN: Autism Spectrum Disorder rates are rising in the US, handwashing is effective for C. diff prevention, and PROMISE 1 trial results have been reported.

All told, 68% of the group receiving a full dose of MDMA no longer qualified for a PTSD diagnosis compared to 29% in the active-placebo control group.

The Global Head of Neurodegeneration for Genentech talks about the progress of 2 promising monoclonal antibodies.

The agency warns that the seizure and bipolar disorder medication can cause hemophagocytic lymphohistiocytosis, a rare but very serious immune system reaction.

Brexanolone received breakthrough therapy designation in September 2016, underscoring the significant unmet need in women suffering from postpartum depression.

An Alzheimer’s diagnosis may cause fear, but the broad spectrum of cognitive impairment means some physicians can continue to practice despite the disease.

Current research shows that positive parenting strategies are linked with improved social-emotional development, but gaps in analysis persist.

Irritability was associated with widespread neural activation or increased activity in the insula, caudate, dorsolateral and ventrolateral prefrontal cortex, and inferior parietal lobule.

The NDA acceptance comes just days after the FDA issued a Refusal to File letter to Alkermes for its investigational MDD therapy.

Next generation sequencing technology is coming on strong in the clinical setting. The FDA would like to help it better reach the market.

Investigators noted promising results for secondary outcomes but demonstrated no difference for the primary outcome of reducing hospital visits due to self-harm.

The antipsychotic was approved by the FDA in 2016 on the backing of what researchers now consider unsubstantial clinical evidence.

The Global Burden of Disease study found that US mortality has improved since 1990 — but has been caused by worse health measures.

Global studies show the practice is still rare, but growing in countries to have legalized it.

A new assessment of the association between alcoholism and brain structure is emphasized by current data indicating a major increase of 106.7% in alcohol use disorder in the US population aged 65 years or older.